Unreported / Non-Citable
Background
Amide Beverage acquired U.S. Patent No. 8,350,077 in November 2024 and sued seventeen defendants—including Amazon, Walmart, Target, CVS, and H-E-B—for infringing claims 1 and 5, which cover products containing “Creatyl-L-Leucine and at least one low-molecular-weight organic or mineral acid.” The common accused product was Bang energy drink, manufactured by Vital Pharmaceuticals. Vital distributed these drinks nationwide through PepsiCo (which supplied most defendants) and directly to H-E-B.
H-E-B, a Texas-based retailer, moved to sever its claim from the consolidated action and transfer the severed case to the Western District of Texas, San Antonio Division, arguing that it was improperly joined with retailers in other distribution channels and that San Antonio was a clearer convenience for its operations.
The Court’s Holding
The court denied H-E-B’s motion to sever and transfer. Under 35 U.S.C. § 299 (Leahy-Smith America Invents Act), joinder is permissible in patent cases only when (1) claims arise from the same transaction, occurrence, or series thereof related to making, using, or selling the same accused product, and (2) common questions of fact exist. The court found both requirements satisfied: all defendants sold Bang energy drinks containing the same allegedly infringing ingredient combination (flavor variations did not alter the patented formulation), and all claims traced to a common supply chain originating with Vital. Common factual questions existed on claim construction, infringement, and damages calculations.
On the venue issue, the court held that H-E-B failed to demonstrate that San Antonio was “clearly more convenient” than the Eastern District of Texas, where H-E-B maintained regular business operations and committed alleged acts of infringement. The party seeking transfer bears the burden of showing good cause—a standard higher than mere preponderance and lower than clear and convincing evidence. The court noted that severance and transfer would fragment the litigation and require duplicate judicial work on identical issues.
Key Takeaways
- Multiple defendants can be properly joined in a patent suit even if they compete directly, provided the claims arise from a common series of transactions related to the same accused product sourced from a common origin.
- The “same accused product” requirement looks to whether products are the same in respects relevant to the patent claims, not trivial variations; here, different flavors of Bang energy drinks shared the same allegedly infringing chemical formulation.
- A common manufacturer and distribution network—even if some defendants purchased indirectly through an intermediary distributor—can establish the “logical relationship” and “aggregate of operative facts” needed for joinder under § 299.
- A movant for venue transfer must affirmatively demonstrate that the alternative forum is “clearly more convenient”; courts presume the plaintiff’s chosen venue is appropriate and will not transfer without strong showing.
- Courts have considerable discretion to deny severance and transfer when doing so would preserve judicial economy and avoid duplication of work across multiple forums.
Why It Matters
This decision clarifies the gatekeeping function of 35 U.S.C. § 299 in patent cases with multiple defendants. Patent holders seeking to consolidate claims against numerous retailers and distributors often face severance motions. The court here rejected H-E-B’s argument that its different supply channel (direct purchase from manufacturer rather than through distributor) and different geographic footprint (Texas-based but smaller than national chains) warranted separation. The decision confirms that the statute’s “same series of transactions” language encompasses supply chains where multiple independent purchasers obtain identical accused products from a single source, and that the statute does not contain a “competitor carveout.”
For defendants and their counsel, the ruling demonstrates heightened difficulty in obtaining severance and transfer absent truly distinct factual inquiries or clear venue convenience. The court’s emphasis on avoiding fragmentation and duplicate litigation—even where severance and transfer are technically permissible under Rule 21—signals that multi-defendant patent cases will remain consolidated where the alleged infringement shares common supply, product formulation, and patent claims, even when defendants occupy different positions in the commercial chain.